Allurion Technologies Announces New Clinical Data on the Elipse® Balloon at ObesityWeek® 2020
10.11.2020 15:00:00 EET | Business Wire | Press release
Allurion Technologies, a pioneering leader in the development of innovative, scalable and trusted weight loss experiences, today announced new clinical data on the Elipse Balloon at ObesityWeek 2020. The Allurion Program features the Elipse Balloon, the world’s first and only procedureless weight loss device. The balloon is designed to remain in the stomach for 4 months and is paired with a Bluetooth® connected scale and Allurion smartphone app and a supervised nutritional program.
In Long-Term Efficacy of the Elipse Gastric Balloon System: An International Multicenter Study, Dr. Roberta Ienca and colleagues report on 509 patients who received the Elipse Balloon and were followed for one year. After 4 months of Elipse Balloon treatment patients achieved weight loss of 14.4 ± 7.7kg or 13.9 ± 6.4% of total body weight. At one-year follow-up, 95% of this weight loss was sustained.
In Sequential Elipse Balloon Treatment: 1-Year Weight Loss Results Approximates Bariatric Surgery Results, Dr. Roberta Ienca and colleagues report on 42 patients treated with sequential Elipse Balloons. Between one and five months following the passing of the first Elipse Balloon, a second balloon was placed. After 4 months, mean weight loss and percent total body weight loss were 14.7 ± 4.4kg and 14.4 ± 3.6%, respectively. The second balloon resulted in an additional 8.8 ± 5.7kg and 10.0 ± 6.5% weight loss, respectively. In total, sequential balloon treatment resulted in weight loss of 22.0 +/- 9.0kg or 22.8 +/- 8.8%, and a body mass index (BMI) decrease of 8.1kg/m2 from baseline.
“Both of these studies demonstrate the potential that the Allurion Program has in providing consumers with long-term and sustainable results,” said Dr. Shantanu Gaur, co-founder and CEO of Allurion. “Additionally, this data indicates that consumers can achieve life-changing results without needing to undergo surgery, endoscopy or anesthesia.”
“The Elipse Balloon provides my patients with a primary weight loss tool and an alternative to weight loss surgery,” said Dr. Alberto Pagan, Clinica CINIB, Palma de Mallorca, Spain. “These results underscore how the Allurion Program can deliver both short and long-term results that meet the expectations of my patients.”
“The clinical data presented at Obesity Week is reflective of the increasing demand for our product around the world,” said Benoit Chardon, Executive Vice President Commercial for Allurion. “We have tripled the number of patients treated in the past year and have created a reputation for clinical results that providers and patients can trust.”
About Allurion Technologies
Allurion Technologies is dedicated to helping people realize their full potential with innovative, scalable and trusted experiences. The company's flagship product, the Allurion Program, is a 360-degree weight loss experience featuring the Elipse Balloon, the world’s first and only swallowable, procedureless gastric balloon for weight loss. Learn more about the Elipse Balloon and Allurion online at www.allurion.com, on Facebook at www.fb.com/allurion or on Twitter @alluriontech.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201110005027/en/
Contact information
Whitney Cypes
+1 (408)-547-7531
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Medisca and EUROAPI Form Strategic Partnership to Strengthen API Access for Pharmaceutical Compounding7.10.2026 17:07:00 EEST | Press release
Medisca and EUROAPI have formed a strategic partnership focused on expanding API access for pharmaceutical compounding, creating differentiated access in North America and establishing a broader framework for international growth and peptide collaboration. For more than three decades, Medisca has built its business around the evolving needs of pharmaceutical compounders. That starts with the products it chooses to bring to market but extends much further to the manufacturers behind them, the documentation and technical information supporting them, and the quality systems that carry those products through to the customer. The partnership with EUROAPI advances that approach. Under the new strategic partnership, Medisca becomes EUROAPI’s first strategic distribution partner focused on bringing its European-manufactured APIs to the North American compounding market. The collaboration includes exclusive supply arrangements for selected APIs and creates a framework to expand the offering ove
iQmetrix Launches Vendor Managed Inventory Integration with Valor Communication7.10.2026 17:00:00 EEST | Press release
iQmetrix, the global provider of Intelligent Commerce Operating Systems for telecom, is launching a Vendor Managed Inventory integration with Valor Communication, a factory-direct wireless accessory manufacturer and distributor serving carriers, retailers, and dealers since 1997. Built into the iQmetrix Intelligent Commerce Operating System, the integration connects Valor's assortment directly to the platform telecom retailers already run their business on – so replenishment runs on real sell-through data instead of guesswork, and approved accessories move from Valor's floor to the peg without manual reordering. The integration will be available to retailers across the iQmetrix client base. The addition of Valor Communication marks another step in the rapid expansion of the iQmetrix Partner Ecosystem, bringing clients a growing network of integrated partners that work natively inside the platform they already run their business on. This press release features multimedia. View the full
Hightouch Names Matthew Lubeck General Manager, EMEA7.10.2026 16:40:00 EEST | Press release
Hightouch, the leader in data and AI for marketing, has named Matthew Lubeck General Manager, EMEA. Based in London, Lubeck will lead all of Hightouch's go-to-market functions across EMEA as the company helps brands in the region move to agentic marketing. Hightouch already has a strong foundation in Europe, with offices in London and Paris, and native-speaking teams in France, the German-speaking markets, Italy, the Nordics, Benelux, and the Middle East. It supports EU data residency and runs inside each customer's own data warehouse, so customer data never has to be copied into another platform. Brands across the region use Hightouch, including Accor, HelloFresh, Currys, Telenor, Salomon, Bolt, Nando's, and Depop. The company is also growing its Middle East presence, with a new team in Dubai focused on the UAE and Saudi Arabia. Lubeck's appointment follows more than 100 percent growth for Hightouch in each of the past two years, and its $150 million Series D earlier this year. Lubeck
Lenovo Announces Tech World @ CES 2027: Defining the Next Era of Hybrid AI7.10.2026 16:01:00 EEST | Press release
Lenovo, the global technology powerhouse, today announced that its annual global innovation event will return to CES® 2027 in Las Vegas. Hosted at Sphere and part of the CES Keynote lineup, Tech World will bring together a visionary lineup of speakers and breakthrough innovations with a first-of-its-kind immersive technology and music experience. As well as unveiling the latest in Lenovo’s innovations, Tech World will unite global technology leaders and leading voices on stage to discuss the future of AI. Together, they will explore how hybrid AI can empower people and unlock new possibilities for business and society. As demand grows for responsible AI leadership, the event will provide a defining moment at the start of 2027 to consider AI’s role in unlocking human potential, sustaining the planet, and driving global progress. “AI is entering a new phase, where every individual and every enterprise should be empowered to transform data into real value,” said Yuanqing Yang, Lenovo Chai
Rivercell Launches With $25 Million to Build Data Platforms and AI Models That Predict How Human Cells Respond to Treatment7.10.2026 16:00:00 EEST | Press release
Rivercell, a Paris-based biotechnology and AI company building its own data infrastructure on how human cells respond to any treatment and training a world model of the cell that can predict those responses, today announced a $25 million seed round led by HV. HCVC, Alven and Bpifrance Digital Venture also participated in the round, which will fund the scale-up of Rivercell’s proprietary data generation platform, the expansion of its wet lab in Paris (a lab working with chemicals and biological samples), and the launch of its AI Virtual Cell program. Being indication-agnostic, Rivercell's world model can drive groundbreaking discovery across any cell behavior that leads to disease because it learns the underlying rules of how human cells respond to drugs and genetic changes, not the features of a single disease. Rivercell was started in summer 2025 by CEO Yann Fleureau, the engineer-turned-entrepreneur behind AI company Cardiologs, joined in 2026 by CSO Eric Durand, an AI scientist and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom